Soriot taps Asia hands for senior AZ team
This article was originally published in Scrip
Executive Summary
As AstraZeneca re-invents itself, one way or another it's all about people. From the top-down impact of the sweeping strategic review conducted by new CEO Pascal Soriot, by way of the thousands of research roles that will be relocated, to the roughly 5,000 positions that will disappear across R&D and SG&A functions over the next four years, many, many individuals will be affected.